Well after a month following the initial release of “positive lab results for COVID-19 testing,” Kontrol Energy (CSE: KNR) has finally released some details surrounding the detection limits of its COVID-19 BioCloud Device as well as the current status of commercialization. Admittedly however, details still remain scarce overall.
The company reported this morning that as part of its commercialization strategy, a lower detection limit of 50 SARs-COV-2 virus particles has been established for its devices. While not an overly technical term, its the first hard data that has been provided in terms of detection capabilities of the device.
The determination of this detection limit, as per the company, was tested under independent laboratory conditions over multiple tests. The device was exposed to the live virus at multiples that include 10,000, 5,000, 1,000, 100, 50 and 5 viruses. To ensure repeatability of the response, the test is said to have been conducted a number of times.
In terms of production, Kontrol revealed this morning that it “continue to advance towards production of BioCloud units in November.” The company is currently seeking a multitude of certifications to meet regional requirements, include CSE, CE and UL. Finally, the company indicated that it has sufficient resources to complete commercialization with approximately $3.0 million in cash on hand.
Kontrol Energy last traded at $3.25 on the CSE.
Information for this briefing was found via Sedar, Y-Charts, and Kontrol Energy Systems. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
